Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | June 29, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 708,151 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 39,341 · Balance 708,151 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person.
Revolution Medicines, Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,656 |
Last balance in matching sequence
After 2026-06-29 transaction · row 10
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
10 source rowsRow 1 · 2026-06-29 · Exercise / conversion · Acquired 2,955 · Balance 27,236 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2: Includes 1,191 restricted stock units. Row 2 · 2026-06-29 · Sale · Disposed 300 · Balance 26,936 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F3: The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 3 · 2026-06-29 · Sale · Disposed 900 · Balance 26,036 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F4: The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 4 · 2026-06-29 · Sale · Disposed 1,100 · Balance 24,936 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F5: The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 5 · 2026-06-29 · Sale · Disposed 858 · Balance 24,078 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F6: The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 6 · 2026-06-29 · Sale · Disposed 300 · Balance 23,778 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F7: The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 7 · 2026-06-29 · Sale · Disposed 100 · Balance 23,678 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2: Includes 1,191 restricted stock units. Row 8 · 2026-06-29 · Sale · Disposed 600 · Balance 23,078 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F8: The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 9 · 2026-06-29 · Sale · Disposed 541 · Balance 22,537 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F9: The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 10 · 2026-06-29 · Sale · Disposed 881 · Balance 21,656 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F10: The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.54 · Expires 2034-06-19 | Direct | 13,000 |
Reported balance
After 2026-06-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-29 · Exercise / conversion · Disposed 2,955 · Balance 13,000 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F11: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.
F2: Includes 1,191 restricted stock units.
F3: The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5: The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6: The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7: The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8: The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9: The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10: The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F11: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 23:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,687 | $14.59 | $155,923.33 |
DisclosureSEC source: 0001104659-22-062607 · tm2215879-4_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,146 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.59 to $14.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 78,750 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042768 · tm2211665-4_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042768 · tm2211665-4_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,833 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-21-061913 · tm2115244-2_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-05-03 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on May 3, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 88,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061913 · tm2115244-2_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,333 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.